EXTON, Pa., April 10, 2019 /PRNewswire/ -- Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year in the EU multiple sclerosis (MS) market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results